ClinicalTrials.gg
CompletedNCT02937116Updated Oct 14, 2022Results posted

First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors

A Phase 1 interventional study of IBI308 and IBI308\Cisplatinum\Pemetrexed in Cancer, Solid Tumor, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-10-14.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
233
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is to determine the safety, tolerability and efficacy of IBI308 monotherapy or in combination with chemotherapy in patients with certain types of advanced solid tumors. Another purpose is to determine the pharmacokinetics, pharmacodynamics and immunogenicity of IBI308.

Read the detailed description

This is a study which consists of phase 1a study (dose escalation stage) and phase 1b study (expansion stage). Phase 1a study will adopt the classical 3+3 dose escalation design, exploring safety and tolerance of 4 dose cohorts (1mg/kg, 3mg/kg, 200mg and 10mg/kg) and determining the recommended dose for phase 1b study. Phase 1b is expansion study of 8 cohorts which will evaluate anti-tumor efficacy and safety of eight IBI308 monotherapy or in combination with chemotherapy. Cohort A is IBI308 monotherapy for advanced melanoma. Cohort B is IBI308 monotherapy for advanced digestive system carcinoma or neuroendocrine neoplasm after failure or intolerance of first line standard therapy. Cohort C is IBI308 monotherapy for advanced non-small cell lung cancer (NSCLC) after failure or intolerance of first line standard therapy. Cohort D is IBI308 in combination with cisplatin and pemetrexed for treatment naïve locally advanced, recurrent or metastatic non-squamous NSCLC. Cohort E is IBI308 in combination with gemcitabine and cisplatin for treatment-naïve locally advanced, recurrent or metastatic squamous NSCLC. Cohort F is IBI308 in combination with oxaliplatin and capecitabine for treatment naïve locally advanced gastric or gastroesophageal junction adenocarcinoma. Cohort G is IBI308 in combination with etoposide and cisplatin for treatment naïve locally advanced, recurrent or metastatic high grade(G3) neuroendocrine tumor. Cohort H is IBI308 in combination with irinotecan and 5-FU for advanced high grade(G3) neuroendocrine tumor after failure of first line standard therapy. Phase 1a and 1b consist of screening period (28 days before enrollment), treatment period and follow up period (every 3 months until death or the end of study). In phase 1a, dose limiting toxicity (DLT) will be recorded for up to 28 days after the 1st dose of IBI308. Efficacy will be evaluated by RECIST v1.1. Adverse events will be monitored throughout the study. Further exploration of pharmacokinetic/pharmacodynamics and immunogenicity information will be assessed throughout the trial.

02

Conditions studied

  • Cancer, Solid Tumor

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 233 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) performance status grade 0 or 1
  • Adequate bone marrow, liver, and renal function defined as: 1) >= 1.5* 10\^9 cells/litre (L); 2) >=100 x 10\^9 cells/L; 3) >= 9 gram/deciliter (g/dL); 4) (ALT) and aspartate aminotransferase (AST) \<= 2.5 * (ULN) for participants without hepatic cell cancer and hepatic , ALT and AST \<= 5 * ULN for participants with hepatic cell cancer or hepatic metastasis; 5) Total (TBIL) \< 1.5 * ULN for participants without hepatic cell cancer, hepatic metastasis and confirmed/suspicious Gilbert syndrome, TBIL \< 3 * ULN for participants with hepatic cell cancer, hepatic metastasis or confirmed/suspicious Gilbert syndrome; 6) Creatinine determined by serum creatinine levels \<=1.5 * ULN or a calculated of >= 50 mL/min/1.73 m\^2; 7) urine protein -\~+, 24 hour urine \< 1 gram for participants with urine protein ++ or above; 8) and international normalized ratio \<= 1.5 * ULN; 9) thyroid stimulating hormone and free thyroxine 4 within normal range
  • Tumor type

    • Phase 1a: advanced solid tumors after failure of standard therapy
    • Phase 1b Cohort A: or histologically confirmed advanced melanoma
    • Phase 1b Cohort B: cytologically or histologically confirmed advanced of the digestive system after failure of at least 1 line of standard therapy
    • Phase 1b Cohort C: cytologically or histologically confirmed advanced NSCLC without known epithelial growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangement after failure of standard therapy
    • Phase 1b Cohort D: treatment naive cytologically or histologically confirmed inoperable locally advanced (stage IIIB) or advanced (stage IV) nsNSCLC without known EGFR mutation and ALK rearrangement, participants with disease recurrence or progression within 6 months after completion of prior platinum doublet-based chemotherapy regimen as or adjuvant therapy are not eligible
    • Phase 1b Cohort E: Cytologically or histologically confirmed, treatment naïve locally advanced, recurrent or metastatic squamous NSCLC without known EGFR mutation and ALK rearrangement. Participants with Stage IIIB NSCLC who progressed within 6 months after completion of platinum-based chemotherapy are not eligible.
    • Phase 1b Cohort F: Histologically confirmed locally advanced, recurrent or metastatic gastric or esophagogastric junction adenocarcinoma without known amplification.
    • Phase 1b Cohort G: Cytologically or histologically confirmed, treatment naïve locally advanced, recurrent or metastatic high grade(G3) neuroendocrine tumor with Ki-67>20%.
    • Phase 1b Cohort H: Cytologically or histologically confirmed advanced high grade(G3) neuroendocrine tumor with Ki-67>20% after failure of first line standard therapy. Participants progressed within 6 months after completion of adjuvant or neoadjuvant chemotherapy are eligible.
  • At least 1 measurable site of disease per v1.1

Exclusion criteria

Exclusion Criteria:

  • Prior treatment of any antibody of or PD-L1
  • Prior treatment of ipilimumab, unless all the following requirements are met:

    • Full resolution of ipilimumab related adverse effects (including immune related adverse effects) and no treatment for these adverse events (AEs) for at least 4 weeks prior to the time of enrollment
    • Minimum of 12 weeks from the first dose of ipilimumab and >6 weeks from the last dose
    • No history of severe immune related adverse effects from ipilimumab ( Grade 4; CTCAE Grade 3 requiring treatment >4 weeks)
    • Unequivocal PD following a dose of ipilimumab
  • infection
  • Active or infection
  • Uncontrolled complication including but not limited to :

    • cardiovascular disease such as uncontrolled or symptomatic arrhythmias or congestive heart failure
    • History of stroke, myocardial infarction or intracranial hemorrhage within 6 months prior to the enrolment
  • History or risk of disease
  • Known interstitial lung disease
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
233 participants (actual)

Study arms

  • Experimental
    Phase 1a

    Participants will receive IBI308 1mg/kg, 3mg/kg or 10mg/kg intravenous every 2 weeks, or 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity. Drug: IBI308

    Drug: IBI308

  • Experimental
    Phase 1b Cohort A

    Participants will receive IBI308 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment. Drug: IBI308

    Drug: IBI308

  • Experimental
    Phase 1b Cohort B

    Participants will receive IBI308 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment. Drug: IBI308

    Drug: IBI308

  • Experimental
    Phase 1b Cohort C

    Participants will receive IBI308 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment. Drug: IBI308

    Drug: IBI308

  • Experimental
    Phase 1b Cohort D

    Participants will receive IBI308 200mg in combination with cisplatin 75mg/m2 and pemetrexed 500mg/m2 intravenously every 3 weeks for upto 4 cycles, and those who haven't progressed will receive maintenance treatment of IBI308 200mg in combination with pemetrexed 500mg/m2 intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment. Drug: IBI308/Cisplatinum/Pemetrexed

    Drug: IBI308\Cisplatinum\Pemetrexed

  • Experimental
    Phase 1b Cohort E

    Participants will receive IBI308 200mg and cisplatin 75mg/m2 intravenously every 3 weeks in combination with gemcitabine 1250mg/m2 intravenously day 1 and 8 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment. Drug: IBI308\\gemcitabine\\cisplatin

    Drug: IBI308\cisplatin\gemcitabine

  • Experimental
    Phase 1b Cohort F

    Participants will receive IBI308 200mg and oxaliplatin 130mg/m2 intravenously every 3 weeks in combination with capecitabine 1000mg/m2 orally day 1 to 14 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment. Drug: IBI308\\oxaliplatin\\capecitabine

    Drug: IBI308\oxaliplatin\capecitabine

  • Experimental
    Phase 1b Cohort G

    Participants will receive IBI308 200mg in combination with cisplatin 75mg/m2 intravenously and etoposide 100mg/m2 intravenously day 1 to 3 of every 3 weeks for upto 6 cycles. Those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment. Drug: IBI308\\etoposide\\cisplatin

    Drug: IBI308\etoposide\cisplatin

  • Experimental
    Phase 1b Cohort H

    Participants will receive IBI308 200mg in combination with irinotecan 125mg/m2 intravenously day 1and 8 and 5-FU 1000mg/m2 intravenously day 1 to 3 of every 3 weeks for upto 6 cycles.Those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment. Drug: IBI308\\irinotecan\\5-FU

    Drug: IBI308\irinotecan\5-FU

Interventions

  • DrugIBI308
  • DrugIBI308\Cisplatinum\Pemetrexed
  • DrugIBI308\cisplatin\gemcitabine
  • DrugIBI308\oxaliplatin\capecitabine
  • DrugIBI308\etoposide\cisplatin
  • DrugIBI308\irinotecan\5-FU
06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Dose-limiting Toxicities (DLTs)

    Time frame: Up to 28 days in Cycle 1

  2. Number of All Study Participants Who Demonstrate a Tumor Response

    Time frame: Through out the study (up to 2 years)

  3. Objective Response Rate (ORR) According to RECIST 1.1 as Assessed by Independent Review Committee by Investigator

    ORR was defined as the percentage of participants in the analysis population who had achieved BOR of CR or PR according to RECIST 1.1.

    Time frame: Through out the study (up to 2 years)

Secondary outcomes

  1. PFS According to RECIST 1.1 as Assessed by Investigator

    Time frame: Through out the study (up to 2 years)

  2. DOR According to RECIST 1.1 as Assessed by Investigator

    Time frame: Through out the study (up to 2 years)

  3. TTR According to RECIST 1.1 as Assessed by Investigator

    Time frame: Through out the study (up to 2 years)

  4. OS for Participants

    Time frame: Through out the study

  5. Area Under the Concentration-time Curve From Zero Time (Predose) to the Time of the Last Measurable Concentration (AUC0-t)

    Time frame: Cycle 1: pre-dose, post-dose at 0, 1, and 6 hours, and Days 2, 3, 8, 15, and 22, and 29

  6. Maximum Concentration (Cmax) of Sintilimab in Solid Tumor Participants

    Time frame: Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29

  7. Time to Maximum Concentration (Tmax) of Sintilimab in Solid Tumor Participants

    Time frame: Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29

  8. The Half-life (t1/2) of IBI308 in Plasma After Single Dose Administration

    Time frame: Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29

  9. Volume of Distribution of IBI308 in Plasma After Single Dose Administration

    Time frame: Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29

  10. Clearance of IBI308 in Plasma After Single Dose Administration

    Time frame: Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29

07

Results

Posted Feb 21, 2021

Participant flow

Participant flow — Overall Study
MilestoneSolid Tumors: Sintilimab 1mg/kg Q2W (Part A1)Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2)Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3)Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4)MEL: Sintilimab 200mg Q3W (Cohort A)Malignant Tumor of the Digestive System or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B)NSCLC: Sintilimab 200mg Q3W (Cohort C)nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D)scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E)Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H)
Started333322873721202077
Completed000000000000
Not completed333322873721202077

Outcome measures

PrimaryNumber of Participants Experiencing Dose-limiting Toxicities (DLTs)
Time frame:
Up to 28 days in Cycle 1
Reported as:
Number · Participants
Number of Participants Experiencing Dose-limiting Toxicities (DLTs)
ParticipantsSolid Tumors: Sintilimab 1mg/kg Q2W (Part A1)Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2)Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3)Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4)MEL: Sintilimab 200mg Q3W (Cohort A)Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B)NSCLC: Sintilimab 200mg Q3W (Cohort C)nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D)scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E)Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H)
Number of Participants Experiencing Dose-limiting Toxicities (DLTs)0000————————
PrimaryNumber of All Study Participants Who Demonstrate a Tumor Response
Time frame:
Through out the study (up to 2 years)
Reported as:
Number · Participants
Number of All Study Participants Who Demonstrate a Tumor Response
ParticipantsSolid Tumors: Sintilimab 1mg/kg Q2W (Part A1)Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2)Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3)Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4)MEL: Sintilimab 200mg Q3W (Cohort A)Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B)NSCLC: Sintilimab 200mg Q3W (Cohort C)nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D)scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E)Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H)
Number of All Study Participants Who Demonstrate a Tumor Response0101113513111731
PrimaryObjective Response Rate (ORR) According to RECIST 1.1 as Assessed by Independent Review Committee by Investigator

ORR was defined as the percentage of participants in the analysis population who had achieved BOR of CR or PR according to RECIST 1.1.

Time frame:
Through out the study (up to 2 years)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR) According to RECIST 1.1 as Assessed by Independent Review Committee by Investigator
percentage of participantsSolid Tumors: Sintilimab 1mg/kg Q2W (Part A1)Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2)Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3)Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4)MEL: Sintilimab 200mg Q3W (Cohort A)Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B)NSCLC: Sintilimab 200mg Q3W (Cohort C)nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D)scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E)Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H)
Objective Response Rate (ORR) According to RECIST 1.1 as Assessed by Independent Review Committee by Investigator————4.5 (0.1 to 22.8)14.9 (8.2 to 24.2)13.5 (4.5 to 28.8)61.9 (38.4 to 81.9)55.0 (31.5 to 76.9)85.0 (62.1 to 96.8)42.9 (9.9 to 81.6)14.3 (0.4 to 57.9)
SecondaryPFS According to RECIST 1.1 as Assessed by Investigator
Time frame:
Through out the study (up to 2 years)
Reported as:
Median · Days
PFS According to RECIST 1.1 as Assessed by Investigator
DaysSolid Tumors: Sintilimab 1mg/kg Q2W (Part A1)Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2)Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3)Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4)MEL: Sintilimab 200mg Q3W (Cohort A)Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B)NSCLC: Sintilimab 200mg Q3W (Cohort C)nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D)scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E)Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H)
PFS According to RECIST 1.1 as Assessed by Investigator————62.0 (59.0 to 125.0)66.0 (64.0 to 95.0)84.0 (60.0 to 187.0)377.0 (92.0 to NA)194.0 (160.0 to 239.0)230.0 (189.0 to 287.0)NA (NA to NA)NA (68.0 to NA)
SecondaryDOR According to RECIST 1.1 as Assessed by Investigator
Time frame:
Through out the study (up to 2 years)
Reported as:
Median · Days
DOR According to RECIST 1.1 as Assessed by Investigator
DaysSolid Tumors: Sintilimab 1mg/kg Q2W (Part A1)Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2)Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3)Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4)MEL: Sintilimab 200mg Q3W (Cohort A)Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B)NSCLC: Sintilimab 200mg Q3W (Cohort C)nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D)scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E)Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H)
DOR According to RECIST 1.1 as Assessed by Investigator————NA (NA to NA)NA (86.0 to NA)368.0 (190.0 to NA)NA (NA to NA)170.5 (58.0 to NA)181.0 (146.0 to 221.0)NA (NA to NA)NA (NA to NA)
SecondaryTTR According to RECIST 1.1 as Assessed by Investigator
Time frame:
Through out the study (up to 2 years)
Reported as:
Median · Days
TTR According to RECIST 1.1 as Assessed by Investigator
DaysSolid Tumors: Sintilimab 1mg/kg Q2W (Part A1)Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2)Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3)Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4)MEL: Sintilimab 200mg Q3W (Cohort A)Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B)NSCLC: Sintilimab 200mg Q3W (Cohort C)nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D)scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E)Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H)
TTR According to RECIST 1.1 as Assessed by Investigator————63.0 (NA to NA)64.0 (61.0 to 70.0)63.0 (60.0 to 189.0)63.0 (62.0 to 120.0)62.0 (58.0 to 68.0)63.0 (62.0 to 65.0)62.0 (62.0 to 63.0)62.0 (62.0 to 62.0)
SecondaryOS for Participants
Time frame:
Through out the study
Reported as:
Median · Days
OS for Participants
DaysSolid Tumors: Sintilimab 1mg/kg Q2W (Part A1)Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2)Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3)Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4)MEL: Sintilimab 200mg Q3W (Cohort A)Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B)NSCLC: Sintilimab 200mg Q3W (Cohort C)nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D)scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E)Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H)
OS for Participants————518.0 (349.0 to NA)342.0 (218.0 to 441.0)431.0 (196.0 to 562.0)566.0 (158.0 to NA)461.0 (308.0 to NA)NA (287.0 to NA)NA (NA to NA)NA (NA to NA)
SecondaryArea Under the Concentration-time Curve From Zero Time (Predose) to the Time of the Last Measurable Concentration (AUC0-t)
Time frame:
Cycle 1: pre-dose, post-dose at 0, 1, and 6 hours, and Days 2, 3, 8, 15, and 22, and 29
Reported as:
Geometric mean · h*ug/ml
Area Under the Concentration-time Curve From Zero Time (Predose) to the Time of the Last Measurable Concentration (AUC0-t)
h*ug/mlSolid Tumors: Sintilimab 1mg/kg Q2W (Part A1)Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2)Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3)Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4)MEL: Sintilimab 200mg Q3W (Cohort A)Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B)NSCLC: Sintilimab 200mg Q3W (Cohort C)nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D)scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E)Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H)
Area Under the Concentration-time Curve From Zero Time (Predose) to the Time of the Last Measurable Concentration (AUC0-t)4800 ± 8.212300 ± 35.239800 ± 14.510800 ± 49.3————————
SecondaryMaximum Concentration (Cmax) of Sintilimab in Solid Tumor Participants
Time frame:
Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29
Reported as:
Geometric mean · ug/ml
Maximum Concentration (Cmax) of Sintilimab in Solid Tumor Participants
ug/mlSolid Tumors: Sintilimab 1mg/kg Q2W (Part A1)Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2)Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3)Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4)MEL: Sintilimab 200mg Q3W (Cohort A)Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B)NSCLC: Sintilimab 200mg Q3W (Cohort C)nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D)scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E)Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H)
Maximum Concentration (Cmax) of Sintilimab in Solid Tumor Participants21.9 ± 11.369.7 ± 12.2220 ± 13.454.6 ± 50.5————————
SecondaryTime to Maximum Concentration (Tmax) of Sintilimab in Solid Tumor Participants
Time frame:
Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29
Reported as:
Median · hours
Time to Maximum Concentration (Tmax) of Sintilimab in Solid Tumor Participants
hoursSolid Tumors: Sintilimab 1mg/kg Q2W (Part A1)Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2)Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3)Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4)MEL: Sintilimab 200mg Q3W (Cohort A)Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B)NSCLC: Sintilimab 200mg Q3W (Cohort C)nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D)scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E)Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H)
Time to Maximum Concentration (Tmax) of Sintilimab in Solid Tumor Participants1.05 (1.05 to 1.08)2.07 (2.07 to 2.08)2.27 (1.10 to 2.33)1.93 (1.08 to 2.13)————————
SecondaryThe Half-life (t1/2) of IBI308 in Plasma After Single Dose Administration
Time frame:
Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29
Reported as:
Geometric mean · Days
The Half-life (t1/2) of IBI308 in Plasma After Single Dose Administration
DaysSolid Tumors: Sintilimab 1mg/kg Q2W (Part A1)Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2)Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3)Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4)MEL: Sintilimab 200mg Q3W (Cohort A)Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B)NSCLC: Sintilimab 200mg Q3W (Cohort C)nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D)scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E)Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H)
The Half-life (t1/2) of IBI308 in Plasma After Single Dose Administration17 ± 7.312.7 ± 44.612.5 ± 26.416.1 ± 32.6————————
SecondaryVolume of Distribution of IBI308 in Plasma After Single Dose Administration
Time frame:
Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29
Reported as:
Geometric mean · L
Volume of Distribution of IBI308 in Plasma After Single Dose Administration
LSolid Tumors: Sintilimab 1mg/kg Q2W (Part A1)Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2)Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3)Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4)MEL: Sintilimab 200mg Q3W (Cohort A)Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B)NSCLC: Sintilimab 200mg Q3W (Cohort C)nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D)scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E)Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H)
Volume of Distribution of IBI308 in Plasma After Single Dose Administration5.02 ± 24.05.14 ± 18.75.95 ± 10.57.2 ± 45.0————————
SecondaryClearance of IBI308 in Plasma After Single Dose Administration
Time frame:
Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29
Reported as:
Geometric mean · ml/h
Clearance of IBI308 in Plasma After Single Dose Administration
ml/hSolid Tumors: Sintilimab 1mg/kg Q2W (Part A1)Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2)Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3)Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4)MEL: Sintilimab 200mg Q3W (Cohort A)Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B)NSCLC: Sintilimab 200mg Q3W (Cohort C)nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D)scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E)Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H)
Clearance of IBI308 in Plasma After Single Dose Administration8.53 ± 20.711.7 ± 33.313.7 ± 15.912.9 ± 61.1————————

Adverse events

Collected over Up to approximately 90 days (through Final Database cut-off date of 30-Oct-2017) for Phase Ia (Part A1 to A4); Up to approximately 90 days (through Final Database cut-off date of 17-Apr-2019) for Phase Ib (Cohort A to F); Up to approximately 90 days (through Final Database cut-off date of 30-Sep-2019) for Phase Ib (Cohort G to H);. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1)0/3 (0%)1/3 (33.3%)3/3 (100%)
Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2)2/3 (66.7%)2/3 (66.7%)3/3 (100%)
Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3)3/3 (100%)1/3 (33.3%)3/3 (100%)
Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4)1/3 (33.3%)1/3 (33.3%)3/3 (100%)
MEL: Sintilimab 200mg Q3W (Cohort A)12/22 (54.5%)0/22 (0%)18/22 (81.8%)
Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B)57/87 (65.5%)18/87 (20.7%)82/87 (94.3%)
NSCLC: Sintilimab 200mg Q3W (Cohort C)25/37 (67.6%)11/37 (29.7%)35/37 (94.6%)
nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D)9/21 (42.9%)3/21 (14.3%)19/21 (90.5%)
scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E)8/20 (40%)9/20 (45%)20/20 (100%)
Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F)3/20 (15%)6/20 (30%)20/20 (100%)
Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G)0/7 (0%)2/7 (28.6%)7/7 (100%)
Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H)0/7 (0%)1/7 (14.3%)7/7 (100%)
Most frequent serious events
Showing 10 of 42
Most frequent serious events
EventSolid Tumors: Sintilimab 1mg/kg Q2W (Part A1)Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2)Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3)Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4)MEL: Sintilimab 200mg Q3W (Cohort A)Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B)NSCLC: Sintilimab 200mg Q3W (Cohort C)nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D)scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E)Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H)
Lung infectionInfections and infestations1/32/30/30/30/221/875/371/210/200/201/70/7
Pancreatitis acuteGastrointestinal disorders0/30/30/31/30/220/870/370/210/200/200/70/7
PneumonitisRespiratory, thoracic and mediastinal disorders0/31/30/30/30/221/870/370/210/201/200/70/7
Respiratory failureRespiratory, thoracic and mediastinal disorders1/30/30/30/30/220/870/370/210/200/200/70/7
Biliary tract infectionInfections and infestations0/30/31/30/30/221/870/370/210/200/200/70/7
Blood bilirubin increasedInvestigations0/30/31/30/30/221/870/370/210/200/200/70/7
Platelet count decreasedInvestigations0/30/30/30/30/220/871/370/213/204/200/70/7
DiarrhoeaGastrointestinal disorders0/30/30/30/30/220/870/371/210/200/200/71/7
AnaemiaBlood and lymphatic system disorders0/30/30/30/30/221/870/371/210/200/201/70/7
Bone marrow failureBlood and lymphatic system disorders0/30/30/30/30/220/870/370/211/200/201/70/7
Most frequent other events
Showing 10 of 197
Most frequent other events
EventSolid Tumors: Sintilimab 1mg/kg Q2W (Part A1)Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2)Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3)Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4)MEL: Sintilimab 200mg Q3W (Cohort A)Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B)NSCLC: Sintilimab 200mg Q3W (Cohort C)nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D)scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E)Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H)
HyperbilirubinaemiaHepatobiliary disorders0/30/30/30/30/221/870/370/210/202/207/71/7
Upper respiratory tract infectionInfections and infestations3/32/30/31/30/225/873/372/210/200/200/71/7
Aspartate aminotransferase increasedInvestigations2/30/32/33/35/2228/876/376/212/205/202/74/7
HypokalaemiaMetabolism and nutrition disorders3/31/30/30/30/2211/872/371/212/203/203/71/7
White blood cell count decreasedInvestigations0/31/30/30/35/2214/874/377/2118/2010/205/75/7
AnaemiaBlood and lymphatic system disorders2/31/31/32/32/2237/8710/379/2117/2012/206/74/7
NauseaGastrointestinal disorders0/30/30/30/30/223/873/379/218/203/202/76/7
Decreased appetiteMetabolism and nutrition disorders0/32/30/31/30/225/876/378/218/202/203/76/7
Neutrophil count decreasedInvestigations1/31/30/30/32/225/873/3710/2116/2010/205/74/7
Platelet count decreasedInvestigations0/30/30/31/30/227/872/372/2114/2016/202/70/7

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1)Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2)Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3)Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4)MEL: Sintilimab 200mg Q3W (Cohort A)Malignant Tumor of the Digestive System or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B)NSCLC: Sintilimab 200mg Q3W (Cohort C)nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D)scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E)Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H)Total
Mean44.33 ± 17.01046 ± 15.52448 ± 6.55750 ± 16.09349.13 ± 13.06152.27 ± 11.28055.35 ± 11.20160.52 ± 6.53962.30 ± 6.95158.20 ± 8.60062.86 ± 4.14049.29 ± 11.91254.54 ± 11.291
Sex: Female, Male
Sex: Female, Male(Participants)Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1)Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2)Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3)Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4)MEL: Sintilimab 200mg Q3W (Cohort A)Malignant Tumor of the Digestive System or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B)NSCLC: Sintilimab 200mg Q3W (Cohort C)nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D)scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E)Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H)Total
Female123173065121261
Male210215573116191865172
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1)Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2)Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3)Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4)MEL: Sintilimab 200mg Q3W (Cohort A)Malignant Tumor of the Digestive System or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B)NSCLC: Sintilimab 200mg Q3W (Cohort C)nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D)scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E)Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H)Total
American Indian or Alaska Native0000000000000
Asian333322873721202077233
Native Hawaiian or Other Pacific Islander0000000000000
Black or African American0000000000000
White0000000000000
More than one race0000000000000
Unknown or Not Reported0000000000000
Region of Enrollment
Region of Enrollment(participants)Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1)Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2)Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3)Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4)MEL: Sintilimab 200mg Q3W (Cohort A)Malignant Tumor of the Digestive System or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B)NSCLC: Sintilimab 200mg Q3W (Cohort C)nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D)scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E)Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G)Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H)Total
China333322873721202077233
08

Study locations

1 site
  • The fifth medical center of the PLA general hospital
    Beijing, China
09

References and documents

Publications

  • Jiang H, Zheng Y, Qian J, Mao C, Xu X, Li N, Xiao C, Wang H, Teng L, Zhou H, Wang S, Zhu D, Peng B, Shen L, Xu N. Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial. BMC Cancer. 2020 Aug 14;20(1):760. doi: 10.1186/s12885-020-07251-z. PubMed 32795349 ↗
  • Jiang H, Zheng Y, Qian J, Mao C, Xu X, Li N, Xiao C, Wang H, Teng L, Zhou H, Wang S, Zhu D, Sun T, Yu Y, Guo W, Xu N. Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study. Cancer Immunol Immunother. 2021 Mar;70(3):857-868. doi: 10.1007/s00262-020-02738-x. Epub 2020 Oct 17. PubMed 33070260 ↗
  • Wei J, Lu X, Liu Q, Fu Y, Liu S, Li L, Liu F, Fan X, Yang J, Yang Y, Zhao Y, Guan W, Liu B. Efficacy and Safety of Sintilimab in Combination with Concurrent Chemoradiotherapy for Locally Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (SHARED): Study Protocol of a Prospective, Multi-Center, Single-Arm Phase 2 Trial. Cancer Manag Res. 2022 Jun 17;14:2007-2015. doi: 10.2147/CMAR.S355687. eCollection 2022. PubMed 35747712 ↗
  • Jia R, Li Y, Xu N, Jiang HP, Zhao CH, Liu RR, Shi Y, Zhang YY, Wang SY, Zhou H, Xu JM. Sintilimab in Patients with Previously Treated Metastatic Neuroendocrine Neoplasms. Oncologist. 2022 Aug 5;27(8):e625-e632. doi: 10.1093/oncolo/oyac097. PubMed 35647908 ↗
  • Jiang H, Li N, Wang H, Chen Z, Zheng Y, Qian J, Mao C, Xu X, Xiao C, Zhang X, Zhou H, Wang S, Chen W, Yin X, Sun J, Peng B, Teng L, Xu N. Assessment of TMB, PD-L1, and lymphocyte to monocyte ratio as predictive potential in a phase Ib study of sintilimab in patients with advanced solid tumors. Am J Cancer Res. 2021 Sep 15;11(9):4259-4276. eCollection 2021. PubMed 34659886 ↗
  • Zhang J, Wu L, Liu J, Lin M. A metastatic intrahepatic cholangiocarcinoma treated with programmed cell death 1 inhibitor: a case report and literature review. Immunotherapy. 2020 Jun;12(8):555-561. doi: 10.2217/imt-2019-0100. Epub 2020 May 6. PubMed 32372672 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2016 to primary completion in Sep 2020, 47 months.

Results were first posted in Feb 2021, 4 months after primary completion.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's 47 months is above that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2016
First posted
Oct 18, 2016
StartActual
Oct 19, 2016
Primary completionActual
Sep 30, 2020
CompletionActual
Sep 30, 2020
Results first posted
Feb 21, 2021
Last update
Oct 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02937116
Responsible party
Sponsor
First posted
Oct 18, 2016
Start date
Oct 19, 2016
Primary completion
Sep 30, 2020
Completion
Sep 30, 2020
Results posted
Feb 21, 2021
Last update
Oct 14, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sintilimab

Start the discussion